{"id":228,"date":"2026-10-28T01:57:38","date_gmt":"2026-10-28T01:57:38","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=228"},"modified":"2026-10-28T01:57:38","modified_gmt":"2026-10-28T01:57:38","slug":"compound-66-a-dual-ido1-tdo-inhibitor-that-hits-both-the-enzyme-and-the-apo-ido1-shp-2-signaling-axis-drug-intelligence-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/compound-66-a-dual-ido1-tdo-inhibitor-that-hits-both-the-enzyme-and-the-apo-ido1-shp-2-signaling-axis-drug-intelligence-dossier\/","title":{"rendered":"Compound 66: A Dual IDO1\/TDO Inhibitor That Hits Both the Enzyme and the Apo-IDO1\/SHP-2 Signaling Axis \u2014 Drug Intelligence Dossier"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">The problem: catalytic IDO1 inhibition was the wrong &#8212; or at least an incomplete &#8212; hypothesis<\/h2>\n\n\n<p>The IDO1 field has a credibility problem. The selective <em>holo<\/em>-IDO1 inhibitor <strong>epacadostat<\/strong> failed to improve outcomes with pembrolizumab in the Phase III ECHO-301 melanoma trial, and most catalytic inhibitors have followed suit. Two mechanistic blind spots explain much of this: (i) tryptophan catabolism can be <strong>bypassed by TDO<\/strong>, so blocking IDO1 alone leaves the kynurenine pathway running; and (ii) IDO1 is not just an enzyme &#8212; the <strong>heme-free <em>apo<\/em> form<\/strong> is a signaling protein that recruits <strong>SHP-2<\/strong> through phosphorylated ITIM motifs, driving a tolerogenic, pro-tumor program that a purely catalytic inhibitor never touches.<\/p>\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"645\" height=\"356\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/ido_toc.png\" alt=\"\" class=\"wp-image-220\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/ido_toc.png 645w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/ido_toc-300x166.png 300w\" sizes=\"auto, (max-width: 645px) 100vw, 645px\" \/><figcaption class=\"wp-element-caption\">Graphical abstract: VS-15 &#8594; compound 66, a dual IDO1\/TDO inhibitor that targets the heme-free apo-enzyme and attenuates the IDO1\/SHP-2 axis. Reproduced under CC-BY 4.0 &#169; 2026 The Authors (ACS).<\/figcaption><\/figure>\n\n\n<h2 class=\"wp-block-heading\">The strategy: keep the multimodal pharmacology, fix the metabolism<\/h2>\n\n\n<p>This Novara team (Rezzi, Buttic&#232;, Di Martino, Pirali and co-workers, <em>J. Med. Chem.<\/em> 2026) started from <strong>VS-15<\/strong> &#8212; a bis-tryptamine hit (A375 IC<sub>50<\/sub> &#8776; 480 nM) with an unusual profile: it engages <strong>apo-IDO1<\/strong> in pockets A and D and shows balanced IDO1\/TDO activity. The liability was pharmacokinetic: VS-15 is metabolically fragile (~5% residual substrate in mouse liver microsomes). The campaign was therefore a <strong>metabolic-stability rescue that had to preserve a multimodal mechanism<\/strong> &#8212; not the usual potency chase.<\/p>\n\n\n<h2 class=\"wp-block-heading\">The chemistry: a convergent, unsymmetrical urea<\/h2>\n\n\n<p>The key SAR move was replacing a metabolically soft amide\/alkyl tether with a <strong>urea<\/strong> in the side chain. The route is cleanly convergent: an <strong>anthranilamide fragment<\/strong> (2-aminobenzoic acid coupled to tryptamine, EDCI\/HOBt) is joined to a second tryptamine through an <strong>unsymmetrical urea<\/strong> via an activated carbamate. The two indole arms occupy pockets A and D; the central benzene and urea set the geometry.<\/p>\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"2343\" height=\"1254\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/cpd66_scheme.png\" alt=\"\" class=\"wp-image-221\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/cpd66_scheme.png 2343w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/cpd66_scheme-300x161.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/cpd66_scheme-1024x548.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/cpd66_scheme-768x411.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/cpd66_scheme-1536x822.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/cpd66_scheme-2048x1096.png 2048w\" sizes=\"auto, (max-width: 2343px) 100vw, 2343px\" \/><figcaption class=\"wp-element-caption\">Redrawn convergent synthesis of compound 66: an anthranilamide fragment joined to tryptamine through an unsymmetrical urea. Redrawn by Astinova Bio Labs from Rezzi, Buttic&#232; et al., J. Med. Chem. 2026, 69, 18336 (Scheme 5).<\/figcaption><\/figure>\n\n\n<h2 class=\"wp-block-heading\">The binding rationale: targeting the apo (heme-free) pocket<\/h2>\n\n\n<p>Unlike epacadostat-class agents that coordinate the heme iron, compound 66&#8217;s spectroscopic behavior is consistent with engaging the <strong>heme-free apoenzyme<\/strong>. Rendering the IDO1 pocket (apo form, PDB 7B1O) shows the aromatic pocket-A residue <strong>Phe163<\/strong> framing the indole arm &#8212; the kind of hydrophobic anchor the bis-indole scaffold is built to exploit, with no dependence on heme coordination.<\/p>\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"945\" height=\"789\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/ido1_binding_7b1o.png\" alt=\"\" class=\"wp-image-222\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/ido1_binding_7b1o.png 945w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/ido1_binding_7b1o-300x250.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/10\/ido1_binding_7b1o-768x641.png 768w\" sizes=\"auto, (max-width: 945px) 100vw, 945px\" \/><figcaption class=\"wp-element-caption\">apo-IDO1 (PDB 7B1O) with a bound inhibitor in pocket A near Phe163 &#8212; the heme-free conformation compound 66 is proposed to engage. Rendered by Astinova Bio Labs (3Dmol.js).<\/figcaption><\/figure>\n\n\n<h2 class=\"wp-block-heading\">The lead: compound 66<\/h2>\n\n\n<ul class=\"wp-block-list\"><li><strong>Balanced dual inhibition<\/strong> of IDO1 and TDO (enzymatic IC<sub>50<\/sub> values in the low-&#181;M range across the series)<\/li><li><strong>Cellular IDO1 (IFN&#947;-induced) IC<sub>50<\/sub> = 1.10 &#181;M<\/strong> with markedly improved microsomal stability over VS-15<\/li><li><strong>Attenuates the apo-IDO1\/SHP-2 interaction<\/strong> in SKOV-3 cells &#8212; it suppresses the <em>non-catalytic<\/em> signaling arm, not just kynurenine output<\/li><li>Reduces cancer-cell <strong>proliferation and migration<\/strong> (SKOV-3)<\/li><\/ul>\n\n\n<h2 class=\"wp-block-heading\">Why it matters<\/h2>\n\n\n<ul class=\"wp-block-list\"><li><strong>Multimodal by design:<\/strong> a chemical probe that dissects catalytic vs. signaling IDO1 biology with one molecule &#8212; a cleaner alternative to either a pure catalytic inhibitor or full IDO1 degradation.<\/li><li><strong>Dual IDO1\/TDO<\/strong> coverage pre-empts the TDO bypass that likely blunted first-generation agents.<\/li><li>For targets with <strong>dual enzymatic\/scaffolding roles<\/strong>, the scaffold &#8212; not just the active-site warhead &#8212; is the design problem.<\/li><\/ul>\n\n\n<p><strong>Reference &amp; image credit:<\/strong> Rezzi, S. J.; Buttic&#232;, A. et al. &#8220;Discovery of a Dual IDO1\/TDO Inhibitor That Modulates Enzymatic Activity and IDO1\/SHP-2 Signaling.&#8221; <em>J. Med. Chem.<\/em> <strong>2026<\/strong>, <em>69<\/em>, 18336&#8211;18363. DOI: 10.1021\/acs.jmedchem.6c00759. Graphical abstract reproduced under a <strong>CC-BY 4.0<\/strong> license &#169; 2026 The Authors, published by the American Chemical Society. Synthesis scheme redrawn and binding-site figure (apo-IDO1, PDB 7B1O) rendered by Astinova Bio Labs.<\/p>\n\n\n<p><em>Astinova Bio Labs designs and makes molecules like this &#8212; route design, original scheme redrawing, and structure-based binding analysis. <a href=\"https:\/\/astinovabiolabs.com\/\">Talk to us<\/a> about your target.<\/em><\/p>\n\n","protected":false},"excerpt":{"rendered":"<p>A convergent, urea-based dual IDO1\/TDO inhibitor (compound 66) that rescues VS-15&#8217;s metabolism while keeping a multimodal mechanism \u2014 blocking catalysis and the apo-IDO1\/SHP-2 signaling axis. With a redrawn synthesis and an apo-IDO1 binding render.<\/p>\n","protected":false},"author":1,"featured_media":220,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[58,55,53,56,57,37,54],"class_list":["post-228","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-chemistry","tag-chemical-probe","tag-dual-inhibitor","tag-ido1","tag-immuno-oncology","tag-kynurenine-pathway","tag-oncology","tag-tdo"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=228"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/228\/revisions"}],"predecessor-version":[{"id":230,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/228\/revisions\/230"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/220"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}